Detalhe da pesquisa
1.
A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors.
Invest New Drugs
; 38(4): 1067-1076, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31471863
2.
Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08).
Haematologica
; 101(3): 346-55, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26659919
3.
Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors.
Cancer Immunol Immunother
; 63(4): 381-94, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24487961
4.
TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16).
Eur J Cancer
; 201: 113588, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38377773
5.
Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors.
J Immunother Cancer
; 11(11)2023 11 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38243906
6.
A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors.
Cancer Res Commun
; 3(9): 1853-1861, 2023 09 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37712875
7.
An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens.
Int J Gynecol Cancer
; 22(5): 792-800, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22635029
8.
A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas.
Leuk Lymphoma
; 63(1): 117-123, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34407735
9.
SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma.
Blood Adv
; 6(13): 3911-3920, 2022 07 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35537101
10.
A phase I study of the oral platinum agent satraplatin in sequential combination with capecitabine in the treatment of patients with advanced solid malignancies.
Acta Oncol
; 50(7): 1105-10, 2011 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-21184645
11.
Breast cancer patients on endocrine therapy reveal more symptoms when self-reporting than in pivotal trials: an outcome research study.
Oncology
; 76(2): 142-8, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-19158446
12.
Improvement in hereditary hemorrhagic telangiectasia after treatment with the phosphoinositide 3-kinase inhibitor BKM120.
Ann Hematol
; 93(4): 703-4, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23892886
13.
Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy.
Cancers (Basel)
; 11(12)2019 Dec 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31835495
14.
First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).
Eur J Cancer
; 96: 6-16, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29660598
15.
Combining chemotherapy and low-molecular-weight heparin for the treatment of advanced breast cancer: results on clinical response, transforming growth factor-beta 1 and fibrin monomer in a phase II study.
Blood Coagul Fibrinolysis
; 18(5): 415-23, 2007 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-17581315
16.
Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.
J Clin Oncol
; 23(23): 5314-22, 2005 Aug 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-15955899
17.
Short Peptide Vaccine Induces CD4+ T Helper Cells in Patients with Different Solid Cancers.
Cancer Immunol Res
; 4(1): 18-25, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26563311
18.
Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study.
Eur J Cancer
; 41(5): 702-7, 2005 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-15763645
19.
A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function.
Cancer Chemother Pharmacol
; 75(1): 87-95, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25377157
20.
A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function.
Cancer Chemother Pharmacol
; 74(5): 1089-98, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25253045